Korro Bio, Inc. (KRRO)

Korro Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	2.27	-	-	-
Gross Profit	2.27	-	-	-
Selling, General & Admin	41.87	36.54	21.39	14.06
Research & Development	52.31	48	37.61	21.43
Operating Expenses	94.18	84.53	59	35.49
Operating Income	-91.91	-84.53	-59	-35.49
Other Non Operating Income (Expenses)	8.47	3.39	0.98	13.54
Pretax Income	-83.44	-81.15	-58.02	-21.96
Income Tax Expense	0.14	0.03	0.01	0
Net Income	-83.58	-81.17	-58.03	-21.96
Net Income to Common	-83.58	-81.17	-58.03	-21.96
Shares Outstanding (Basic)	9	2	0	4
Shares Outstanding (Diluted)	9	2	0	4
Shares Change (YoY)	483.30%	499.32%	-94.26%	-
EPS (Basic)	-9.37	-53.08	-227.42	-4.94
EPS (Diluted)	-9.37	-53.08	-227.42	-4.94
Free Cash Flow	-77.98	-75.12	-58.86	-36.54
Free Cash Flow Per Share	-8.74	-49.12	-230.65	-8.22
Gross Margin	100.00%	-	-	-
Operating Margin	-4047.12%	-	-	-
Profit Margin	-3680.36%	-	-	-
Free Cash Flow Margin	-3433.55%	-	-	-
EBITDA	-88.35	-80.9	-56.49	-33.9
D&A For EBITDA	3.57	3.63	2.51	1.6
EBIT	-91.91	-84.53	-59	-35.49

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q